Prophylactic nitrate therapy in angina pectoris--is there an optimal treatment regimen?

Br J Clin Pharmacol

Cardiovascular Medicine, Clinical Research and Development, Astra Hässle AB, Sweden.

Published: August 1992

1. Nitrates have a place in the prophylactic treatment of patients with angina pectoris. Their efficacy is not in doubt. 2. However, there may be some practical problems associated with their use, such as unreliable absorption, short duration of action, treatment-induced headache, development of nitrate tolerance and a suggested rebound phenomenon observed during intermittent dosing. Furthermore, patient convenience with treatment schedule and patient compliance have to be considered during prophylactic treatment. The present article discusses how many of these problems may be solved by selection of formulation as well as nitrate compound. 3. The development of controlled-release formulations producing sufficiently high nitrate plasma concentration during part of the day followed by nitrate-poor rather than nitrate-free interval, have the potential to prevent both nitrate tolerance and rebound phenomenon, and produce a sufficiently long duration of action with a convenient once daily regimen.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1381218PMC
http://dx.doi.org/10.1111/j.1365-2125.1992.tb04144.xDOI Listing

Publication Analysis

Top Keywords

prophylactic treatment
8
duration action
8
nitrate tolerance
8
rebound phenomenon
8
prophylactic nitrate
4
nitrate therapy
4
therapy angina
4
angina pectoris--is
4
pectoris--is optimal
4
treatment
4

Similar Publications

Background: Noise sources in paediatric dental offices include machinery and children's cries and screams. Although the presence of occupational noise-induced hearing loss (ONIHL) among dental operators is established, preventive measures such as ear protection devices (EPDs) are not frequently employed as prophylactic intervention. The primary aim of this study was to quantitatively assess the noise levels in paediatric dental clinics and to qualitatively evaluate the operators' perception of noise with and without the use of EPDs.

View Article and Find Full Text PDF

Importance: There are limited data to guide practices to reduce surgical site infections following sacral neuromodulation; however, many surgeons prescribe prophylactic postoperative antibiotics after device implantation.

Objective: The aim of the study was to compare the proportion of patients with sacral neuromodulation device-associated surgical site infections after use of prophylactic postoperative antibiotics versus none.

Study Design: This was a multicenter retrospective cohort study of patients undergoing sacral neuromodulation device implantation at 11 institutions from January 2014 to December 2023, comparing outcomes in patients who did versus did not receive prophylactic postoperative antibiotic treatment.

View Article and Find Full Text PDF

Case: An 8-year-old girl with NF1 and congenital tibial dysplasia with significant bilateral tibial bowing underwent McFarland procedures. Now age 22 with 14-year follow-up indicating sustained correction and healing of her bilateral limb deformities.

Conclusion: This case illustrates the McFarland procedure provided adequate corrective treatment of this deformity and remains a success at long-term follow-up.

View Article and Find Full Text PDF

Despite novel prophylactic regimens, chronic graft-versus-host disease (cGVHD) remains a challenging complication after allogeneic hematopoietic cell transplantation. Chronic GVHD can affect multiple organs and reduces quality of life, and treatment can cause serious side effects. In the last ten years, the drugs ibrutinib, ruxolitinib, belumosudil and axatilimab were FDA-approved for cGVHD.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

L & J Bio, Co., Ltd, Seoul, Songpa-Gu, Korea, Republic of (South).

Background: Neurofibrillary tangles (NFTs), along with amyloid beta plaque, are neuropathological aggregates of Alzheimer's Disease (AD). Hyperphosphorylated tau is responsible for the NFTs formation and further neurodegeneration in AD. The hippocampal region and the entorhinal cortex (EC) have been a major focus of AD research because the deposits of hyperphosphorylated tau protein and NFT in these regions are correlated with memory deficits.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!